The pharmaceutical firms have added funding that will help advance Takeda-backed Aquinnah Pharmaceuticals' neurodegenerative disease drugs.

The Perelman School of Medicine, the School of Engineering and Applied Science and the Office of the Vice-Provost of Research have joined forces to launch Penn Health-Tech.

Red Apple Group, Wilson Sonsini Goodrich & Rosati, Mitsubishi Tanabe Pharma Corporation and Alexandria Real Estate Equities have all invested in the antibiotics developer.

The WuXi PharmaTech-backed molecular diagnostics technology developer has raised $27m that will go to commercialising its IDgenetix product.

The clinical trials technology provider has now raised more than $66m in the space of 18 months, attracting GV, Sanofi Ventures, Amgen Ventures and DRx Capital for its latest round.

The $1.5m UConn Innovation Fund, established in August last year, has made its first three investments, namely Torigen Pharmaceuticals, Bioarray Genetics and Shoreline Biome.

The cloud-based drug prescription platform has closed a round that included new investor GV and SR One, a backer since seed stage.

Padlock raised about $18m since inception in 2013/14 by venture capital firm Atlas Ventures and academics Paul Thompson and Kerri Mowen from a consortium including a series A round with Johnson & Johnson and Merck Ventures, and later added Index Ventures and GlaxoSmithKline.

Microdermics, a spinout of UBC, has developed a microneedle that injects medication into the upper skin layer, avoiding blood vessels and nerve tissue.